Damon R. Reed

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

49h-index9.5kcitations325works1.42yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(115), Cancer Immunotherapy and Biomarkers(45), Childhood Cancer Survivors' Quality of Life(40), Cancer Genomics and Diagnostics(32), CAR-T cell therapy research(31)

Publications325 total

Impact of Quality of Life on Work Productivity Among Adolescent and Young Adult Cancer Survivors

Journal of Adolescent and Young Adult Oncology·2026

Data from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Supplementary Figure S2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Supplementary Table S1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Figure 2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Supplementary Table S2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Supplementary Table S3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Figure 3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Supplementary Table S4 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Table 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Supplementary Figure S1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Figure 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Table 2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Supplementary Figure S3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Figure 4 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Supplementary Table S5 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

2026Open Access

Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcome in Sarcoma

Clinical Cancer Research·2026

Systemic Therapy Outcomes for Soft Tissue Leiomyosarcoma Patients in an Era of Next-Generation Sequencing

JCO oncology advances.·2026Open Access

Data from A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group

2026Open Access

Appendix1 from A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group

2026Open Access

page 1 of 17Next →

Frequent Co-authors

Scott H. Okuno(8), Scott M. Schuetze(7), Robert G. Maki(7), Gwendolyn P. Quinn(7), Brian A. Van Tine(6), Steven Attia(6), Richard F. Riedel(6), Denise K. Reinke(6), Scott C. Borinstein(6), Margaret von Mehren(6), Sujana Movva(5), Lara E. Davis(5), Shreyaskumar Patel(5), Mark Agulnik(5), Melissa Burgess(4), Vanessa Bolejack(4), James Hu(4), Dennis A. Priebat(4), Sant P. Chawla(4), Christopher W. Ryan(4)